A cancer terminator virus eradicates both primary and distant human melanomas

Cancer Gene Therapy

Volumn 15, Issue 5, 2008, Pages 293-302

  Sarkar, D ^a,b,d   Su, Z Z ^a,b   Park, E S ^a   Vozhilla, N ^a,b   Dent, P ^b   Curiel, D T ^c   Fisher, P B ^a,b,d  

^a Columbia University Medical Center ^*  (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Apoptosis; Cancer terminator virus (CTV); mda 7 IL 24; Metastatic melanoma; PEG 3 promoter

Indexed keywords

INTERLEUKIN 24;

ADENOVIRUS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DISEASE COURSE; GENE REPLICATION; HUMAN; HUMAN CELL; MELANOMA; PRIORITY JOURNAL; TUMOR VIRUS; VIRUS GENE; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; DISEASE PROGRESSION; GENE THERAPY; HUMANS; MELANOMA; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; TERMINATOR REGIONS (GENETICS); TRANSPLANTATION, HETEROLOGOUS; VIRUS REPLICATION;

ADENOVIRIDAE; MUS MUSCULUS;

EID: 41949127542     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.14     Document Type: Article

References (53)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer Statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
2. Weinstock MA. Issues in the epidemiology of melanoma. Hematol Oncol Clin North Am 1998; 12: 681-698.
3. Herlyn M. Human melanoma: development and progression. Cancer Metastasis Rev 1990; 9: 101-112.
4. Rigel DS, Carucci JA. Malignant melanoma: prevention, early detection,and treatment in the 21st century. CA Cancer J Clin 2000; 50: 215-236.
5. Diagnosis and treatment of early melanoma. NIH Consens Statement 1992; 10: 1-26.
6. Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation,growth and progression. Oncogene 1995; 11: 2477-2486.
7. Huang EY, Madireddi MT, Gopalkrishnan RV, Leszczyniecka M, Su ZZ, Lebedeva IV et al. Genomic structure,chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene 2001; 20: 7051-7063.
8. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 2004; 22: 929-979.
9. Jiang H, Su ZZ, Lin JJ, Goldstein NI, Young CSH, Fisher PB. The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc Natl Acad Sci USA 1996; 93: 9160-9165.
10. Su ZZ, Madireddi MT, Lin JJ, Young CSH, Kitada S, Reed JC et al. The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. Proc Natl Acad Sci USA 1998; 95: 14400-14405.
11. Lebedeva IV, Su ZZ, Chang Y, Kitada S, Reed JC, Fisher PB. The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells. Oncogene 2002; 21: 708-718.
12. Sarkar D, Su ZZ, Lebedeva IV, Sauane M, Gopalkrishnan RV, Valerie K et al. mda-7 (IL-24) mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK. Proc Natl Acad Sci USA 2002; 99: 10054-10059.
13. Fisher PB, Sarkar D, Lebedeva IV, Emdad L, Gupta P, Sauane M et al. Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Toxicol Appl Pharmacol 2007; 224: 300-307.
14. Fisher PB. Is mda-7/IL-24 a 'magic bullet' for cancer? Cancer Res 2005; 65: 10128-10138.
15. Gupta P, Su ZZ, Lebedeva IV, Sarkar D, Sauane M, Emdad L et al. mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol Ther 2006; 111: 596-628.
16. Lebedeva IV, Sauane M, Gopalkrishnan RV, Sarkar D, Su ZZ, Gupta P et al. mda-7/IL-24: exploiting cancer's Achilles' heel. Mol Ther 2005; 11: 4-18.
17. Sarkar D, Lebedeva IV, Gupta P, Emdad L, Dent P, Curiel DT et al. Melanoma differentiation associated gene-7 (mda-7)/IL-24: a 'magic bullet' for cancer therapy? Expert Opin Biol Ther 2007; 7: 577-586.
18. Lebedeva IV, Emdad L, Su ZZ, Gupta P, Sauane M, Sarkar D et al. mda-7/IL-24,novel anticancer cytokine: focus on bystander antitumor,radiosensitization and antiangiogenic properties and overview of the phase I clinical experience. Int J Oncol 2007; 31: 985-1007.
19. Madireddi MT, Su ZZ, Young CSH, Goldstein NI, Fisher PB. Mda-7,a novel melanoma differentiation associated gene with promise for cancer gene therapy. Adv Exp Med Biol 2000; 465: 239-261.
20. Su ZZ, Lebedeva IV, Gopalkrishnan RV, Goldstein NI, Stein CA, Reed JC et al. A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells. Proc Natl Acad Sci USA 2001; 98: 10332-10337.
21. Sarkar D, Su ZZ, Vozhilla N, Park ES, Gupta P, Fisher PB. Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proc Natl Acad Sci USA 2005; 102: 14034-14039.
22. Saeki T, Mhashilkar A, Swanson X, Zou-Yang XH, Sieger K, Kawabe S et al. Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo. Oncogene 2002; 21: 4558-4566.
23. Ramesh R, Mhashilkar AM, Tanaka F, Saito Y, Branch CD, Sieger K et al. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Res 2003; 63: 5105-5113.
24. Su ZZ, Lebedeva IV, Sarkar D, Gopalkrishnan RV, Sauane M, Sigmon C et al. Melanoma differentiation associated gene-7, mda-7/IL-24, selectively induces growth suppression,apoptosis and radiosensitization in malignant gliomas in a p53-independent manner. Oncogene 2003; 22: 1164-1180.
25. Caudell EG, Mumm JB, Poindexter N, Ekmekcioglu S, Mhashilkar AM, Yang XH et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol 2002; 168: 6041-6046.
26. Su ZZ, Emdad L, Sauane M, Lebedeva IV, Sarkar D, Gupta P et al. Unique aspects of mda-7/IL-24 antitumor bystander activity: establishing a role for secretion of MDA-7/IL-24 protein by normal cells. Oncogene 2005; 24: 7552-7566.
27. Fisher PB, Gopalkrishnan RV, Chada S, Ramesh R, Grimm EA, Rosenfeld MR et al. mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic. Cancer Biol Ther 2003; 2: S23-S37.
28. Cunningham CC, Chada S, Merritt JA, Tong A, Senzer N, Zhang Y et al. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. Mol Ther 2005; 11: 149-159.
29. Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N et al. Intratumoral injection of INGN 241,a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther 2005; 11: 160-172.
30. El-Aneed A. Current strategies in cancer gene therapy. Eur J Pharmacol 2004; 498: 1-8.
31. Wu Q, Moyana T, Xiang J. Cancer gene therapy by adenovirus-mediated gene transfer. Curr Gene Ther 2001; 1: 101-122.
32. Lebedeva IV, Su ZZ, Sarkar D, Fisher PB. Restoring apoptosis as a strategy for cancer gene therapy: focus on p53 and mda-7. Semin Cancer Biol 2003; 13: 169-178.
33. Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000; 18: 723-727.
34. Haviv YS, Curiel DT. Conditional gene targeting for cancer gene therapy. Adv Drug Deliv Rev 2001; 53: 135-154.
35. Haviv YS, Curiel DT. Engineering regulatory elements for conditionally-replicative adeno-viruses. Curr Gene Ther 2003; 3: 357-385.
36. Nettelbeck DM, Rivera AA, Balague C, Alemany R, Curiel DT. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res 2002; 62: 4663-4670.
37. Banerjee NS, Rivera AA, Wang M, Chow LT, Broker TR, Curiel DT et al. Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures. Mol Cancer Ther 2004; 3: 437-449.
38. Wildner O, Morris JC, Vahanian NN, Ford Jr H, Ramsey WJ, Blaese RM. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther 1999; 6: 57-62.
39. Su ZZ, Sarkar D, Emdad L, Duigou GJ, Young CSH, Ware J et al. Targeting gene expression selectively in cancer cells using the progression elevated gene-3 promoter. Proc Natl Acad Sci USA 2005; 102: 1059-1064.
40. Sarkar D, Su ZZ, Vozhilla N, Park ES, Randolph A, Valerie K et al. Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice. Cancer Res 2005; 65: 9056-9063.
41. Sarkar D, Lebedeva IV, Su ZZ, Park ES, Chatman L, Vozhilla N et al. Eradication of therapy-resistant human prostate tumors using a cancer terminator virus. Cancer Res 2007; 67: 5434-5442.
42. Su ZZ, Shi Y, Fisher PB. Subtraction hybridization identifies a transformation progression-associated gene PEG-3 with sequence homology to a growth arrest and DNA damage-inducible gene. Proc Natl Acad Sci USA 1997; 94: 9125-9130.
43. Su ZZ, Goldstein NI, Jiang H, Wang MN, Duigou GJ, Young CSH et al. PEG-3,a nontransforming cancer progression gene,is a positive regulator of cancer aggressiveness and angiogenesis. Proc Natl Acad Sci USA 1999; 96: 15115-15120.
44. Su ZZ, Shi Y, Fisher PB. Cooperation between AP1 and PEA3 sites within the progression elevated gene-3 (PEG-3) promoter regulates basal and differential expression of PEG-3 during progression of the oncogenic phenotype in transformed rat embryo cells. Oncogene 2000; 19: 3411-3421.
45. Su ZZ, Shi Y, Friedman R, Qiao L, McKinstry R, Hinman D et al. PEA3 sites within the progression elevated gene-3 (PEG-3) promoter and mitogen-activated protein kinase contribute to differential PEG-3 expression in Ha-ras and v-raf oncogene transformed rat embryo cells. Nucleic Acids Res 2001; 29: 1661-1671.
46. Sarkar D, Su ZZ, Fisher PB. Cancer terminator viruses (CTV): unique conditionally replication competent bipartite adenoviruses. In: Hermonat PL (ed). Cancer and Gene Therapy, 2007. Transworld Research Network, 2007; in press.
47. Sarkar D, Su ZZ, Fisher PB. Unique conditionally replication competent bipartite adenoviruses - cancer terminator viruses: efficacious reagents for cancer gene therapy. Cell Cycle 2006; 5: 1531-1536.
48. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000; 6: 1134-1139.
49. Johnson L, Shen A, Boyle L, Kunich J, Pandey K, Lemmon M et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent,systemic antitumor agents. Cancer Cell 2002; 1: 325-337.
50. Cascallo M, Capella G, Mazo A, Alemany R. Ras-dependent oncolysis with an adenovirus VAI mutant. Cancer Res 2003; 63: 5544-5550.
51. Huang TG, Savontaus MJ, Shinozaki K, Sauter BV, Woo SL. Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Ther 2003; 10: 1241-1247.
52. Miyahara R, Banerjee S, Kawano K, Efferson C, Tsuda N, Miyahara Y et al. Melanoma differentiation-associated gene-7 (mda-7)/interleukin (IL)-24 induces anticancer immunity in a syngeneic murine model. Cancer Gene Ther 2006; 13: 753-761.
53. Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K et al. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 2006; 66: 1270-1276.